Literature DB >> 11053205

Inhibition of neuroeffector transmission in human vas deferens by sildenafil.

P Medina1, G Segarra, B Torondel, P Chuan, C Domenech, J M Vila, S Lluch.   

Abstract

Sildenafil (0.1 - 30 microM), a cyclic GMP phosphodiesterase 5 (PDE 5) inhibitor, induced inhibition of electrically evoked contractions of ring segments of human vas deferens from 34 vasectomies. Zaprinast (0.1 - 100 microM), another PDE 5 inhibitor, and the nitric oxide (NO) donor sodium nitroprusside (SNP) (0.1 - 100 microM) had no effect on neurogenic contractions. The inhibition induced by sildenafil was not modified by the inhibitor of guanylate cyclase 1H-[1,2,4]oxadiazolo[4,3-a]quinoxaline-1-one (ODQ) (1 - 30 microM) but it was abolished by the K(+) channel blockers tetraethylammonium (TEA, 1 mM), iberiotoxin (0.1 microM) and charybdotoxin (0.1 microM). Sildenafil, zaprinast and SNP did not affect the contractions induced by noradrenaline. SNP (10 microM) caused elevation of cyclic GMP levels that was potentiated by sildenafil (10 microM) and zaprinast (100 microM). ODQ (10 microM) inhibited the increase in cyclic GMP. Sildenafil inhibits adrenergic neurotransmission in human vas deferens. The inhibition is not related to accumulation of cyclic GMP but is probably due to activation of prejunctional large-conductance Ca(2+)-activated K(+) channels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11053205      PMCID: PMC1572414          DOI: 10.1038/sj.bjp.0703657

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  Colocalisation of neuropeptides, nitric oxide synthase and immunomarkers for catecholamines in nerve fibres of the adult human vas deferens.

Authors:  P Y Jen; J S Dixon; J A Gosling
Journal:  J Anat       Date:  1999-11       Impact factor: 2.610

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

Review 3.  Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.

Authors:  J A Beavo; D H Reifsnyder
Journal:  Trends Pharmacol Sci       Date:  1990-04       Impact factor: 14.819

4.  The mechanism of action of Ba2+ and TEA on single Ca2+-activated K+ -channels in arterial and intestinal smooth muscle cell membranes.

Authors:  C D Benham; T B Bolton; R J Lang; T Takewaki
Journal:  Pflugers Arch       Date:  1985-02       Impact factor: 3.657

5.  Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine.

Authors:  S Katsuki; W Arnold; C Mittal; F Murad
Journal:  J Cyclic Nucleotide Res       Date:  1977-02

6.  Purification and characterization of a unique, potent, peptidyl probe for the high conductance calcium-activated potassium channel from venom of the scorpion Buthus tamulus.

Authors:  A Galvez; G Gimenez-Gallego; J P Reuben; L Roy-Contancin; P Feigenbaum; G J Kaczorowski; M L Garcia
Journal:  J Biol Chem       Date:  1990-07-05       Impact factor: 5.157

7.  Effects of sildenafil on human penile blood vessels.

Authors:  P Medina; G Segarra; J M Vila; C Domenech; J B Martínez-León; S Lluch
Journal:  Urology       Date:  2000-09-01       Impact factor: 2.649

8.  Relaxation induced by cGMP phosphodiesterase inhibitors sildenafil and zaprinast in human vessels.

Authors:  P Medina; G Segarra; J B Martínez-León; J M Vila; M Aldasoro; E Otero; S Lluch
Journal:  Ann Thorac Surg       Date:  2000-10       Impact factor: 4.330

9.  Potassium channel inhibitors attenuate neuromodulatory effects of atrial natriuretic factor in the rabbit isolated vas deferens.

Authors:  S Kanwal; G J Trachte
Journal:  J Pharmacol Exp Ther       Date:  1994-01       Impact factor: 4.030

10.  The sulphonylurea receptor may be an ATP-sensitive potassium channel.

Authors:  N C Sturgess; M L Ashford; D L Cook; C N Hales
Journal:  Lancet       Date:  1985-08-31       Impact factor: 79.321

View more
  7 in total

1.  KMUP-1 relaxes rabbit corpus cavernosum smooth muscle in vitro and in vivo: involvement of cyclic GMP and K(+) channels.

Authors:  Rong-Jyh Lin; Bin-Nan Wu; Yi-Ching Lo; Kuo-Pyng Shen; Young-Tso Lin; Chun-Hsiung Huang; Ing-Jun Chen
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Purinergic contraction of the rat vas deferens in L-NAME-induced hypertension: effect of sildenafil.

Authors:  Serap Gur; Suresh C Sikka; Gillian E Knight; Geoffrey Burnstock; Wayne J G Hellstrom
Journal:  Asian J Androl       Date:  2010-03-22       Impact factor: 3.285

Review 3.  Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action.

Authors:  Ibrahim A Abdel-Hamid
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Regulation of smooth muscle contractility by the epithelium in rat vas deferens: role of ATP-induced release of PGE2.

Authors:  Ye Chun Ruan; Zhe Wang; Jian Yang Du; Wu Lin Zuo; Jing Hui Guo; Jie Zhang; Zhong Luan Wu; Hau Yin Wong; Yiu Wa Chung; Hsiao Chang Chan; Wen Liang Zhou
Journal:  J Physiol       Date:  2008-08-28       Impact factor: 5.182

5.  Inhibition by sildenafil of contractility of isolated non-pregnant human myometrium.

Authors:  Aruldhas Blessed Winston; Kaysina Vazhudhi; Sumalya Sen; Elsy Thomas; Santhosh Benjamin; Jacob Peedicayil
Journal:  J Pharmacol Pharmacother       Date:  2015 Jul-Sep

6.  Nitric oxide activates ATP-sensitive potassium channels in mammalian sensory neurons: action by direct S-nitrosylation.

Authors:  Takashi Kawano; Vasiliki Zoga; Masakazu Kimura; Mei-Ying Liang; Hsiang-En Wu; Geza Gemes; J Bruce McCallum; Wai-Meng Kwok; Quinn H Hogan; Constantine D Sarantopoulos
Journal:  Mol Pain       Date:  2009-03-14       Impact factor: 3.395

7.  Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation.

Authors:  Muammer Kendirci; Emad Salem; Wayne Jg Hellstrom
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.